Multaq met its primary endpoint in the trial, reducing the risk of death or hospitalization due to cardiovascular events in patients with atrial fibrillation, when compared to placebo.
Multaq在该试验中达到预期疗效，与安慰剂相比，该药可降低房颤（AF）患者由心血管疾病所致的死亡或住院治疗风险。
The FDA rejected the drug once before, in 2006, after a study in patients with heart failure showed that people in the Multaq group died at twice the rate of those in the placebo group.
在此之前一项针对心衰患者进行的研究显示，服用决奈达隆的患者死亡率是服用安慰剂组的两倍，因此FDA曾于2006年驳回该药的申请。
The FDA rejected the drug once before, in 2006, after a study in patients with heart failure showed that people in the Multaq group died at twice the rate of those in the placebo group.
在此之前一项针对心衰患者进行的研究显示，服用决奈达隆的患者死亡率是服用安慰剂组的两倍，因此FDA曾于2006年驳回该药的申请。
应用推荐